Healthcare-focused investment firm OrbiMed Advisors significantly increased its position in Thermo Fisher Scientific (TMO), according to a recent quarterly disclosure. The filing, which reflects trades made between April 1 and June 30, 2026, shows OrbiMed boosted its holdings by 95%, from 46,500 to 90,700 shares. The total reported value of the stake now stands at $45.47 million.
The transaction occurred during a strong second quarter for Thermo Fisher, in which the company reported a 10% year-over-year revenue increase to $11.99 billion and raised its financial outlook for the full year. As is typical, the 13F filing was released with a delay, disclosing trades that took place in the prior quarter.